8-K: Cross Country Healthcare Q2 Revenue Drops 19% Amid Merger

Cross Country Healthcare reported a 19% year-over-year revenue decline in Q2 2025, with a net loss of $6.7 million, while confirming its merger with Aya Healthcare is expected to close in Q4.

Summary

• Consolidated revenue for Q2 2025 was $274.1 million, a 19% decrease year-over-year and 7% sequentially.
• The company reported a net loss attributable to common stockholders of $6.7 million for Q2 2025, compared to a $16.1 million loss in Q2 2024 and a $0.5 million loss in Q1 2025.
• Diluted EPS was a net loss of $0.20 for Q2 2025, an improvement from a $0.47 loss in Q2 2024 but a larger loss than the $0.02 loss in Q1 2025.
• Adjusted EBITDA for Q2 2025 was $7.6 million, or 2.8% of revenue, down 46% year-over-year and 12% sequentially.
• Adjusted EPS for Q2 2025 was a net loss of $0.01, compared to a profit of $0.10 in Q2 2024 and a loss of $0.07 in Q1 2025.
• Cash flows provided by operations for Q2 2025 were $4.2 million, a 95% decrease year-over-year and 26% sequentially.
• Nurse and Allied Staffing revenue decreased 23% year-over-year to $224.3 million, while Physician Staffing revenue increased 3% year-over-year to $49.8 million.
• The company maintained a healthy balance sheet with $81.2 million in cash and no debt as of June 30, 2025.
• The pending merger transaction with Aya Healthcare, Inc. is expected to close in the fourth quarter of 2025.
• No earnings conference call or forward-looking guidance will be provided due to the pending merger.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While results were 'in line with expectation' and some segments showed growth, the overall consolidated revenue, adjusted EBITDA, and cash flow metrics experienced significant year-over-year declines. The pending merger introduces both potential upside and considerable uncertainty, overshadowing current operational performance.

Positives

• Second quarter results were in line with expectations.
• Client retention rates remain steady with a strong pipeline of Managed Service Provider (MSP) implementations and expansions slated for the second half of 2025.
• Strong performance in Homecare Staffing, with revenue growing more than 30% over the prior year.
• Physician Staffing experienced 3% year-over-year revenue growth, predominantly on favorable mix and price.
• Selling, General & Administrative (SG&A) expenses saw a 5% sequential decline, fueled by further leverage of the low-cost center of excellence in India.
• Healthy balance sheet with $81.2 million of cash on-hand and no debt as of June 30, 2025.
• Net loss attributable to common stockholders improved year-over-year for both the quarter and six-month period.
• Diluted EPS loss improved year-over-year for both the quarter and six-month period.
• Nurse and Allied Staffing contribution income increased 139% year-over-year to $13.9 million.
• Physician Staffing contribution income increased 13% year-over-year and 14% sequentially to $4.6 million.

Negatives

• Consolidated revenue decreased 19% year-over-year and 7% sequentially to $274.1 million for Q2 2025.
• Consolidated gross profit margin decreased 40 basis points year-over-year to 20.4% for Q2 2025.
• Net loss attributable to common stockholders increased significantly sequentially by 1,259% to $6.7 million for Q2 2025.
• Diluted EPS was a net loss of $0.20 for Q2 2025, a larger loss than the $0.02 loss in Q1 2025.
• Adjusted EBITDA decreased 46% year-over-year and 12% sequentially to $7.6 million for Q2 2025.
• Adjusted EBITDA margin decreased 140 basis points year-over-year and 10 basis points sequentially to 2.8% for Q2 2025.
• Adjusted EPS turned to a net loss of $0.01 for Q2 2025, compared to a profit of $0.10 in Q2 2024.
• Cash flows provided by operations significantly decreased by 95% year-over-year to $4.2 million for Q2 2025.
• Nurse and Allied Staffing revenue decreased 23% year-over-year and 7% sequentially to $224.3 million.
• Core travel nurse and allied business continues to normalize, indicating a challenging market environment.
• No shares of common stock were repurchased during the second quarter of 2025.

Risks

• Uncertainty regarding the timing to consummate the proposed Aya Merger.
• Risk that a condition of closing the proposed Aya Merger may not be satisfied or that the closing might otherwise not occur.
• Risk that regulatory approval required for the proposed Aya Merger is not obtained or is obtained subject to unanticipated conditions.
• Diversion of management time on transaction-related issues and disruption of ongoing business operations due to the proposed merger.
• Potential adverse effects on the market price of the common stock due to merger announcements.
• Risk that the proposed merger could adversely affect the ability to retain customers, hire key personnel, and maintain relationships with suppliers and customers.
• Possibility of an event, change, or circumstance that could lead to the termination of the Merger Agreement, potentially requiring the company to pay a termination fee.
• Risk that competing offers for the company will be made.
• Unexpected costs, charges, or expenses resulting from the Aya Merger.
• Potential litigation relating to the Aya Merger against the parties or their directors, managers, or officers.
• Worldwide economic or political changes that affect the markets served, impacting demand for services and profitability.
• Effects from global pandemics, epidemics, or other public health crises.
• Changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, and customer needs.
• Disruptions in global credit and financial markets, including diminished liquidity and credit availability.
• Changes in international trade agreements, including tariffs and trade restrictions.
• Cyber-security vulnerabilities.
• Foreign currency volatility.
• Swings in consumer confidence and spending.
• Costs of providing services.
• Retention of key employees.
• Outcomes of legal proceedings, claims, and investigations.

Future Outlook

The company expects the pending merger transaction with Aya Healthcare to close in the fourth quarter of 2025. Due to the pending transaction, the company will not host an earnings conference call or provide forward-looking guidance. Management stated they continue to make investments to enhance their value proposition for customers and candidates while awaiting the merger closure.

Management Comments

• "Our second quarter results were in line with expectation, reflecting a combination of the momentum in our Homecare and Physician Staffing businesses, as well as our continuing efforts to control costs."
• "We expect that the pending merger transaction with Aya will close in the fourth quarter. And, while we await the closure, we continue to make investments that we believe will further enhance our value proposition for our customers and candidates."

Industry Context

The healthcare staffing industry, particularly the core travel nurse and allied segment, is experiencing normalization after periods of high demand, likely reflecting a shift from pandemic-driven peaks. Despite this, specialized areas like Homecare and Physician Staffing are showing resilience and growth, indicating a diversified demand within the broader healthcare sector. The company's focus on cost control and strategic investments, alongside a significant pending merger, suggests a proactive approach to navigating a dynamic market and consolidating its position.

Stakeholder Impact

• Shareholders: Will experience significant changes due to the pending merger, which is expected to close in Q4. Current financial performance shows declines, but the 'in line with expectation' comment may mitigate immediate negative reactions. The merger's terms will dictate future value.
• Employees: The merger could lead to integration challenges or opportunities, potentially impacting roles and organizational structure.
• Customers: Client retention rates remain steady, and the company is investing to enhance its value proposition, suggesting continued focus on customer service despite the merger.
• Suppliers: Relationships with suppliers are critical and could be affected by the merger's integration process.
• Creditors: The company maintains a healthy balance sheet with no debt and significant borrowing availability, indicating strong liquidity for creditors.

Next Steps

• Closing of the pending merger transaction with Aya Healthcare, Inc. in the fourth quarter of 2025.
• Continued investments to enhance value proposition for customers and candidates.

Key Dates

Recommendation

The company's Q2 2025 results show significant year-over-year declines in key financial metrics like revenue, adjusted EBITDA, and cash flow from operations, reflecting a normalizing market for core staffing services. However, management stated these results were 'in line with expectation,' suggesting the market may have already factored in these trends. The pending merger with Aya Healthcare, expected to close in Q4, is the dominant factor. While the current operational performance is weak, the merger could unlock significant synergies and market position. For existing investors, holding shares to realize the potential value from the merger, rather than selling into a downturn, seems prudent, especially given the 'in line with expectation' comment. New investors might wait for more clarity on the merger's terms and post-merger strategy.

Keywords

Healthcare Staffing, Nurse Staffing, Allied Staffing, Physician Staffing, Workforce Solutions, SEC Filing, Financial Results, Q2 2025, Earnings, Merger, Aya Healthcare, CCRN, Temporary Staffing, Healthcare Workforce